Genvor's AI-Powered Peptides Target $220B Crop Loss Market

TL;DR

**Genvor is a high-risk, pre-revenue biotech play with promising AI-powered peptide tech that could disrupt agriculture, but its success hinges entirely on future partnerships and patent protection.**

AI Summary

Genvor Inc. (GNVR) is an agricultural biotechnology company focused on AI-accelerated peptide technology for sustainable crop protection and performance enhancement. The company reported no revenue for the fiscal year ended September 30, 2025, as it is in the research and development phase, focusing on strategic partnerships rather than internal infrastructure. Key business changes include the successful integration of over 9,000 proprietary synthetic antimicrobial peptides into its BioCypher algorithm, leading to an 85% improvement in training performance. Genvor's lead peptide candidate, GV185, demonstrated strong antifungal activity against major agricultural pathogens like Fusarium graminearum with an IC50 of 2.1, and the company achieved significant technical formulation advancements for liquid aqueous formulations of GV185 and GV197. Risks include the reliance on obtaining and maintaining patent protection, with current U.S. patents expiring between 2031 and 2038, and the uncertainty of pending patent applications. The strategic outlook emphasizes a licensing-first commercialization model to leverage partners' regulatory expertise and distribution networks for global market access.

Why It Matters

Genvor's AI-driven peptide technology could revolutionize sustainable agriculture, offering residue-free solutions to combat the estimated $220 billion in annual global crop losses. For investors, this represents a high-risk, high-reward opportunity in a sector facing increasing demand for eco-friendly alternatives to traditional pesticides, potentially disrupting established chemical players. Employees and customers could benefit from a healthier food supply chain and reduced environmental impact. The company's partnership-driven model aims for capital efficiency, but successful commercialization hinges on securing robust collaborations and navigating a competitive landscape with giants like Bayer and Corteva.

Risk Assessment

Risk Level: high — Genvor is a pre-revenue company, indicating significant financial risk as it has not yet generated income from its operations. The company's success is heavily dependent on its ability to obtain and maintain patent protection, with U.S. patents expiring between 2031 and 2038, and there's no assurance that pending applications will result in issued patents. Furthermore, its commercialization strategy relies entirely on strategic partnerships, which introduces execution risk.

Analyst Insight

Investors should approach Genvor with extreme caution, recognizing its pre-revenue status and reliance on future partnerships and patent success. Monitor progress on licensing agreements and the outcome of pending patent applications, as these will be critical indicators of future viability and potential market penetration.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $220 billion — estimated annual global crop losses (target market for Genvor's technology)
• 85% — improvement in training performance (BioCypher algorithm's third-generation model)
• 9,000 — proprietary synthetic antimicrobial peptides (integrated into BioCypher algorithm)
• 50,000 — designed peptides (in Genvor's extensive library)
• 5 — issued U.S. patents (part of Genvor's intellectual property portfolio)
• 2031 to 2038 — U.S. patent expiration dates (range for Genvor's current patents)
• 34,511,855 — shares of common stock outstanding (as of December 8, 2025)
• 72% — reduction in fungal growth (demonstrated by transgenic corn peptide AGM182 in USDA trials)
• 98% — reduction in aflatoxin contamination (demonstrated by transgenic corn peptide AGM182 in USDA trials)
• 2.1 — IC50 for GV185 (against Fusarium graminearum, indicating strong antifungal activity)

Key Players & Entities

• Genvor Inc. (company) — registrant
• GNVR (company) — ticker symbol
• Dr. Jesse Jaynes (person) — contributor of 9,000 synthetic antimicrobial peptides
• BioCypher Algorithm (company) — proprietary AI-driven peptide discovery platform
• GV185 (company) — lead peptide candidate
• USDA (regulator) — partner in transgenic corn peptide AGM182 trials
• OTC Link ATS (company) — previous trading platform for common stock
• Nevada (regulator) — state of redomiciliation
• Delaware (regulator) — state of incorporation for Old Genvor

FAQ

Risk Factors

• Patent Expiration and Protection [high — legal]: Genvor's competitive advantage relies heavily on its intellectual property, specifically its U.S. patents which are set to expire between 2031 and 2038. The company also has pending patent applications, the success of which is uncertain. Failure to obtain or maintain patent protection could significantly impact its ability to commercialize its peptide technologies.
• Research and Development Phase Dependency [high — operational]: Genvor is currently in the research and development phase and has reported no revenue for the fiscal year ended September 30, 2025. The company's progress is contingent on the successful development and validation of its peptide candidates and the BioCypher algorithm, with no guarantee of future commercial success.
• Reliance on Strategic Partnerships [medium — market]: The company's commercialization strategy is centered on a licensing-first model, depending on strategic partners for regulatory expertise and global distribution networks. The success of this model is subject to the availability and terms of such partnerships, and Genvor has limited control over the market access and commercialization efforts of its partners.
• Technological Development and Integration [medium — operational]: Genvor's core technology involves AI-accelerated peptide development. While the BioCypher algorithm showed an 85% improvement in training performance with 9,000 proprietary peptides, continued advancements and successful integration of new peptides are critical. Any setbacks in algorithm performance or peptide discovery could hinder product development.

Industry Context

Genvor operates in the agricultural biotechnology sector, a rapidly evolving field driven by the need for sustainable solutions to combat crop losses, estimated at $220 billion annually. The industry is characterized by significant R&D investment, a strong emphasis on intellectual property, and increasing adoption of AI for product development. Key trends include the demand for environmentally friendly crop protection methods and performance enhancers, alongside consolidation and strategic partnerships to navigate complex regulatory landscapes and achieve global market penetration.

Regulatory Implications

Genvor's peptide-based agricultural products will be subject to rigorous regulatory review and approval processes in different jurisdictions worldwide. Navigating these requirements, particularly for novel biotechnologies, is critical for market entry. The company's reliance on partners for regulatory expertise highlights the complexity and cost associated with obtaining approvals for new agricultural inputs.

What Investors Should Do

1. Monitor patent application progress and outcomes.
2. Track strategic partnership announcements and deal terms.
3. Evaluate R&D milestones and validation data.

Key Dates

• 2018-09-26: Company incorporated in Florida as 'Allure Worldwide, Inc.' — Marks the initial formation of the corporate entity that would eventually become Genvor Inc.
• 2021-01-11: Entered into Exchange Agreement to acquire Old Genvor Inc. — Initiated the process to acquire the core peptide technology business.
• 2022-03-02: Entered into Merger Agreement to consummate the Acquisition of Old Genvor. — Formalized the merger plan to integrate the target business.
• 2022-05-27: Acquisition of Old Genvor closed; name changed to Genvor Incorporated. — The company officially became Genvor Inc., integrating its AI peptide technology business.
• 2025-09-30: Fiscal year end — Reported zero revenue, indicating the company is still in the R&D phase.

Glossary

BioCypher Algorithm

A proprietary artificial intelligence algorithm developed by Genvor to accelerate the discovery and design of peptides. (This is the core AI technology enabling Genvor's peptide development for crop protection and enhancement.)

Peptide Technology

A class of molecules composed of amino acids, used by Genvor for developing sustainable crop protection and performance enhancement solutions. (Represents Genvor's primary product focus and technological innovation.)

IC50

Half maximal inhibitory concentration, a measure of the potency of a substance in inhibiting a specific biological or biochemical function. (Used to quantify the effectiveness of Genvor's peptide candidate GV185 against fungal pathogens, with a lower IC50 indicating higher potency.)

Proprietary Synthetic Antimicrobial Peptides

Unique, man-made molecules designed by Genvor that have the ability to combat microbial threats in agriculture. (These peptides are the building blocks of Genvor's product pipeline and are integrated into their BioCypher algorithm.)

Licensing-first Commercialization Model

A business strategy where the company focuses on developing and patenting technology, then licenses it to other companies for manufacturing, marketing, and distribution. (Genvor's chosen path to market, relying on partners for global reach and regulatory expertise.)

Year-Over-Year Comparison

As Genvor Inc. is in the research and development phase, the fiscal year ended September 30, 2025, reported no revenue, consistent with its business model. The company has made significant strides in its technological capabilities, notably an 85% improvement in its BioCypher algorithm's training performance through the integration of 9,000 proprietary peptides. New risks related to the dependency on strategic partnerships for commercialization have become more prominent, while existing risks concerning patent protection remain a key concern.

Key Financial Figures

• $0.001 — ction 12(g) of the Act: Common Stock, $0.001 par value (Title of class) Indicate
• $220 billion — ce enhancement, targeting the estimated $220 billion in annual global crop losses attributed

Filing Documents

• gnvr_10q.htm (10-K) — 1161KB
• ex31_1.htm (EX-31.1) — 13KB
• ex31_2.htm (EX-31.2) — 13KB
• ex32_1.htm (EX-32.1) — 5KB
• ex32_2.htm (EX-32.2) — 5KB
• image_021.jpg (GRAPHIC) — 16KB
• image_001.gif (GRAPHIC) — 4KB
• image_001.jpg (GRAPHIC) — 12KB
• image_006.gif (GRAPHIC) — 2KB
• 0001903596-25-000575.txt ( ) — 5160KB
• gnvr-20250930.xsd (EX-101.SCH) — 35KB
• gnvr-20250930_cal.xml (EX-101.CAL) — 42KB
• gnvr-20250930_def.xml (EX-101.DEF) — 166KB
• gnvr-20250930_lab.xml (EX-101.LAB) — 328KB
• gnvr-20250930_pre.xml (EX-101.PRE) — 278KB
• gnvr_10q_htm.xml (XML) — 607KB

Business

Business 4 Item 1A. Risk Factors 15 Item 1B. Unresolved Staff Comments 15 Item 1C. Cybersecurity 15 Item 2.

Properties

Properties 16 Item 3. Legal Proceedings 16 Item 4. Mine Safety Disclosures 17 PART II. Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 17 Item 6. [Reserved] 20 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operation 20 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 25 Item 8. Financial F-1 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 26 Item 9A. Controls and Procedures 26 Item 9B. Other Information 27 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 27 PART III. Item 10. Directors, Executive Officers and Corporate Governance 28 Item 11. Executive Compensation 33 Item 12. Security 36 Item 13. Certain Relationships and Related Transactions, and Director Independence 37 Item 14. Principal Accounting Fees and Services 38 PART IV. Item 15. Exhibits 39 Item 16. Form 10-K Summary 40

Signatures

Signatures 41 Exhibits 2 FORWARD LOOKING This Annual Report on Form 10-K contains forward-looking statements within the meaning of Rule 175 of the Securities Act of 1933, as amended, and Rule 3b-6 of the Securities Act of 1934, as amended, that involve substantial risks and uncertainties. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our industry, our beliefs, and our assumptions. Words such as "anticipate," "expects," "intends," "plans," "believes," "seeks" and "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Form 10-K. Investors should carefully consider all of such risks before making an investment decision with respect to the Company's stock. The following discussion and analysis should be read in conjunction with our financial statements for Genvor Incorporated. Such discussion represents only the best present assessment from our Management. 3 PART I

: Business

Item 1: Business Genvor Incorporated (the "Company" or "Genvor") was incorporated in Florida on September 26, 2018, as "Allure Worldwide, Inc.," and as of November 18, 2019, redomiciled to Nevada. On June 24, 2022, the Company changed its name to from "Allure Worldwide, Inc." to "Genvor Incorporated." The Company was originally formed with the intention of seeking to acquire the assets or shares of an entity actively engaged in business which generates revenues, in exchange for its securities. On January 11, 2021, the Company entered into an Exchange Agreement (the "Purchase Agreement") with Genvor Inc., a Delaware corporation ("Old Genvor") to acquire (the "Acquisition") Old Genvor. On March 2, 2022, the Company and Old Genvor entered into a merger agreement (the "Merger Agreement") to consummate the Acquisition, and pursuant to which a wholly-owned subsidiary of the Company, Genvor Acquisition Corp., a Delaware corporation ("Merger Subsidiary"), merged (the "Merger") with and into Old Genvor, with each share of Old Genvor common stock issued immediately prior to the time of the merger automatically converted into the right to receive one share of common stock of the Company. On May 27, 2022, the Acquisition closed, Merger Subsidiary merged with and into Old Genvor, each share of Old Genvor was exchanged for the right to receive one share of Company common stock, 35,261,871 shares of Company common stock were issued to Old Genvor's pre-merger shareholders (the "Merger Shares"), constituting a change of control of the Company, and Old Genvor became a wholly owned subsidiary of the Company. As a result of these transactions, the Company had 55,261,871 issued and outstanding common shares upon the closing of the Acquisition, and subsequently the Company's original founding shareholders cancelled 18,144,112 shares of Company common stock in connection with the Acquisition. The Company's subsidiary, Genvor Inc., was incorporated under the laws of the State of De

View Full Filing

View this 10-K filing on SEC EDGAR